ArticleJournal of immunological sciences2018
The Impact of Recent Rubella Vaccine Introduction in 5 Countries in The African Region.
Article in Journal of immunological sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 17 citations in OpenAlex.
- The evolving landscape of rubella in the WHO African Region.The Pan African medical journal · 2025Article
- Rubella epidemiology in Lesotho after vaccine introduction: a five-year review, 2018-2022.BMC public health · 2024Article
- On the Path to Measles and Rubella Elimination Following Rubella-Containing Vaccine Introduction, 2000-2023, Namibia.Vaccines · 2024Article
- Estimates of the global burden of Congenital Rubella Syndrome, 1996-2019.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2023Article
- Rubella virus genotype 2B endemicity and related utility of serum-based molecular characterization in Uganda.BMC research notes · 2023Article
- A retrospective 5-year review of rubella in South Africa prior to the introduction of a rubella-containing vaccine.PloS one · 2022Article
- Rubella Eradication: Not Yet Accomplished, but Entirely Feasible.The Journal of infectious diseases · 2021Article
- Rubella seroprevalence using residual samples from the South African measles surveillance program: a cross-sectional analytic study.Human vaccines & immunotherapeutics · 2020Article
- Rubella transmission and the risk of congenital rubella syndrome in Liberia: a need to introduce rubella-containing vaccine in the routine immunization program.BMC infectious diseases · 2019Article
- Epidemiological Pattern of Rubella in Africa: A Review of Selected Sub-Saharan African Countries.Nigerian medical journal : journal of the Nigeria Medical AssociationReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 3 countries.
Funding
Abstract
The World Health Organization (WHO) recommends that countries introduce rubella containing vaccines (RCVs) to reduce rubella circulation and the occurrence of congenital rubella syndrome (CRS). As of June 2017, a total of 18 countries have already introduced or are in the process of introducing RCV in routine child vaccination programs. RCV introduction during 2013 - 2014 in five countries in the Region resulted in a reduction of rubella incidence of 48% to 96% in the post-introduction period as compared to the average incidence in the years before introduction. These results suggest that initial mass vaccination campaigns and introduction of RCVs in routine immunization programs result in significant reduction in rubella incidence and a reduced potential for the occurrence of CRS.
Indexed as
Identifiers
30957104PMC6446993W2927803581What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.